Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab

Haploview: analysis and visualization of LD and haplotype maps

Jeffrey C. Barrett, Ben Fry, Julian Maller et al. · Bioinformatics · 2004 · 14.7K citations · Full text

Life Sciences, Biostatistics, Genetics +17

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny et al. · New England Journal of Medicine · 2004 · 11K citations · Full text

Medicine, Oncology, Pharmacology +15

Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study

Leonard B. Saltz, Stephen Clarke, Eduardo Díaz‐Rubio et al. · Journal of Clinical Oncology · 2008 · 3K citations · Full text

Medicine, Oncology, Pharmacology +12

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

Bruce J. Giantonio, Paul J. Catalano, Neal J. Meropol et al. · Journal of Clinical Oncology · 2007 · 2.3K citations

Medicine, Oncology, Pharmacotherapy +15

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)

Lisa M. McShane, Douglas G. Altman, Willi Sauerbrei et al. · JNCI Journal of the National Cancer Institute · 2005 · 2.1K citations · Full text

Medicine, Biostatistics, Oncology +16